Emerging research from the recent Society of Interventional Radiology (SIR) conference suggests the combination of transarterial radioembolization (TARE) and immunotherapy may offer improved three-year survival outcomes for patients with breast cancer and liver metastases.
For patients with breast cancer liver metastases, the combination of immunotherapy and transarterial radioembolization (TARE) may significantly enhance survival outcomes over other treatment options, according to new research presented at the recent Society of Interventional Radiology (SIR) conference.
In a recent interview, lead study author Amy Deipolyi, M.D., pointed out that approximately one-fifth of breast cancer deaths are due to liver metastasis. In her experience with subspecializing in the treatment of patients with breast cancer, Dr. Deipolyi has found that half of these patients will develop metastatic breast cancer with the metastasis frequently occurring in the liver.
In light of these sobering trends, Dr. Deipolyi and her colleagues sought to compare TARE/immunotherapy to transarterial chemoembolization (TACE)/immunotherapy, TARE/chemotherapy, and TACE/chemotherapy in a total cohort of 418 patients with breast cancer and liver metastases.
In an interventional radiology study involving 418 patients with breast cancer liver metastases, TARE/immunotherapy offered the highest three-year survival rate in comparison to TACE/immunotherapy, TARE/chemotherapy and TACE/chemotherapy.
The study authors found that TARE/immunotherapy offered the highest median overall survival (38 months) and the highest three-year survival rate at 52 percent in comparison to 48 percent for TACE/immunotherapy, 45 percent for TARE/chemotherapy and 40 percent for TACE/chemotherapy.
Dr. Deipolyi said these multicenter comparative study findings align with previous single-center retrospective work comparing Y-90 radioembolization and chemoembolization in the treatment of breast cancer liver metastases.
“The overall impression you get is that Y-90 (radioembolization) yields better imaging results, more objective responses, and is better tolerated with fewer side effects,” posited Dr. Deipolyi, the chief of interventional radiology at the Charleston Area Medical Center in Charleston, W.V., and associate professor at West Virginia University.
Lending further credence to the comparative study findings presented at the SIR conference was the fact that the cohort was drawn from a query of 68 health-care organizations via the federated TriNetX database, which allows real-time access to research data collection from a network of 145 hospital organizations, according to study co-author Frank Annie, Ph.D., a clinical research manager and assistant professor in the Department of Cardiology at the Charleston Area Medical Center in Charleston, W.V.
(Editor’s note: For related content, see “Interventional Radiology Study Shows Low Breast Cancer Recurrence 16 Months After Cryoablation,” “Current Perspectives on PET/CT Imaging in Patients with Metastatic Breast Cancer” and “Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging.”)
For more insights from Drs. Deipolyi and Annie, watch the video below.
Reference
1. Deipolyi A, Annie F, Bryce Y. Chemoembolization vs. radioembolization for breast cancer liver metastasis: retrospective multi-institution observational study. J Vasc Interv Radiol. 2025;36(3):S56-57. Available at: https://www.jvir.org/article/S1051-0443(24)00951-5/fulltext .
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.